Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer
08 oct. 2024 16h05 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a series of ongoing research...
Myriad Genetics and Ultima Genomics to Explore the UG 100™ Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics
03 oct. 2024 09h00 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY and FREMONT, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and Ultima Genomics, Inc., a...
Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
01 oct. 2024 16h05 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and...
AmMax Bio to Present at the Oppenheimer Healthcare Private Company Showcase
27 sept. 2024 08h33 HE
|
AmMax Bio, Inc.
REDWOOD CITY, Calif., Sept. 27, 2024 (GLOBE NEWSWIRE) -- AmMax Bio, Inc., a private clinical-stage biopharmaceutical company developing innovative therapeutics in oncology, today announced that it...
Burning Rock Reports Second Quarter 2024 Financial Results
22 août 2024 23h59 HE
|
Burning Rock Biotech Limited
Burning Rock Reports Second Quarter 2024 Financial Results
Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing
11 juil. 2024 09h00 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY and FREMONT, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing and precision medicine, and Personalis, Inc. (Nasdaq: PSNL)...
Burning Rock Reports First Quarter 2024 Financial Results
29 mai 2024 01h34 HE
|
Burning Rock Biotech Limited
Burning Rock Reports First Quarter 2024 Financial Results
International Myeloma Foundation Celebrates ODAC Meeting Outcome on Minimal Residual Disease (MRD) Testing as an Early Endpoint for the Accelerated Approval of Myeloma Drugs in Clinical Trials: A Huge Win for the Global Myeloma Community
12 avr. 2024 16h08 HE
|
International Myeloma Foundation
International Myeloma Foundation Celebrates ODAC Meeting on Minimal Residual Disease (MRD) Testing as an Early Endpoint for the Accelerated Approval.
Burning Rock Reports Fourth Quarter and Full Year 2023 Financial Results
28 mars 2024 17h16 HE
|
Burning Rock Biotech Limited
Burning Rock Reports Fourth Quarter and Full Year 2023 Financial Results
Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
21 mars 2024 21h40 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, March 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and...